Medivation, Pfizer fall on Alzheimer's study
March 03, 2010 at 11:00 AM EST
Drug stocks edged higher in early trading Wednesday while shares of Medivation Inc. plunged on news that its Alzheimer's disease drug candidate dimebon had failed a key Phase III clinical trial.